Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (3603)	1/15/1998 1:57:00 PM
From: Mr. Pink	Read Replies (1) of 6136

Peter: It was brave of you to go out on a limb and estimate AGPH revenue just prior to the quarterly report. You mentioned that you were going to try and estimate earnings. Note that AGPH's most recent quarter to quarter change in SG+A expense was about +11%. The research budget also increased by a similar amount. This kind of increase might be OK every few quarters, but if it becomes chronic, management's estimated +15% quarter to quarter increase in revenues won't have quite the impact on earnings growth that one might be hoping for. If AGPH can keep a lid on SG+A expenses as well as slowing R+D budget inflation, earnings, and hence the stock price will skyrocket, in my humblest of opinions. Thanks for your posts, Eric

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next